Ractigen Therapeutics
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3b 4th Floor Bldg.1 Biobay 99, Suzhou, J...Phone Number
+8651381996959Website
www.ractigen.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ractigen Therapeutics
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as small activating RNAs (saRNA), to specifically up-regulate targeted endogenous genes for boosting therapeutic protein production. Supporting its core platform, Ractigen Therapeutics has created the SCAD delivery system allowing enhanced biodistribution throughout extrahepatic tissue and built a rich pipeline of first-in-class candidate medicines for patients with unmet genetic disorders.Explore more
Ractigen Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ractigen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Ractigen Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Ractigen Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Ractigen Therapeutics recently announced quarterly report
Check if Ractigen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ractigen Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Ractigen Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Ractigen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ractigen Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Ractigen Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ractigen Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ractigen Therapeutics.
Ractigen Therapeutics financials insights
Gather financial insights about Ractigen Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$48M
2026
Unspecified
$31M
Ractigen Therapeutics Tech Stack
A closer look at the technologies used by Ractigen Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Open Position
Project
Compliance, Intellectual Property, Legal Affairs
New Hire
Executive Move
Funding
Ractigen Therapeutics News & Media
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting...Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 29, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, today announced the successful closing of a new financing round exceeding $31Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
— Peer-reviewed publication details RAG-17's robust translation from "bench to bedside," validating the proprietary SCAD™ delivery platform for CNS-targeted RNAi therapies — — First-in-Human trial met primary safety endpoints with no Serious Adverse Events (SAEs); demonstrated mean...Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and preventing post-treatment weight rebound. NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Ractigen...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ractigen Therapeutics
Sign Up For FreeTo access detailed company insights
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as... Read More
